Biora Therapeutics Divests Preeclampsia Test to Avero Diagnostics
Biora previously operated as a women's health diagnostic company called Progenity, but in mid-2021 shifted its focus to drug delivery and therapeutics.
The firm alleges its competitors infringe its patents describing processes for finding chromosomal abnormalities in fetal cell-free DNA.
Enumera Molecular Acquires Progenity Liquid Biopsy Tech, Raises $12.5M in Series A Round
Progenity will receive an ownership stake in the newly formed venture, which is being headed by its former CSO Matthew Cooper.
Progenity, Natera Jointly Request Dismissal of Patent Litigation
Progenity sought a declaratory judgment from a California court last year that its Innatal NIPT test didn't infringe six patents held by Natera.
Progenity Raises $40M in Private Placement
The firm said it will use the funds to support its operations, to invest in its molecular testing research and development program, and for working capital.